NASDAQ
Indivior Pharmaceuticals, Inc. (INDV)
♥ 665 Thanks from members
Indivior Pharmaceuticals (INDV) demonstrates robust financial performance with a Q2 earnings beat, raised 2026 guidance, and a definitive agreement for an all-stock merger of equals with Supernus Pharmaceuticals to build a diversified CNS leader.